Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus
TUESDAY, Aug. 19, 2025 -- Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute myocardial infarction, and stroke among adults aged 50 years or older, according to a study published online Aug. 9 in Clinical Infectious Diseases.
Emily Rayens, Ph.D., M.P.H., from Kaiser Permanente Southern California in Pasadena, and colleagues conducted a matched cohort analysis of adults aged 50 years and older who received two doses of RZV four weeks to six months apart during April 1, 2018, to Dec. 31, 2020, and were matched in a 1:4 ratio with RZV-unvaccinated individuals. Data were included for 102,766 two-dose RZV-vaccinated adults and 411,064 unvaccinated adults.
The researchers found that when comparing RZV-vaccinated and unvaccinated individuals, the adjusted hazard ratios of HZO, hospitalized acute myocardial infraction, and hospitalized stroke were 0.271, 0.720, and 0.575, respectively. Against HZO, the adjusted RZV effectiveness was 72.9 percent.
"These data suggest that health benefits of RZV immunization may extend beyond the well-described prevention of herpes zoster and postherpetic neuralgia," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including GSK, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Without Biannual Time Shift, Prevalence of Obesity, Stroke May Be Reduced
WEDNESDAY, Sept. 17, 2025 -- The prevalence of obesity and stroke would be reduced with permanent Standard Time (SDT) and Daylight Saving Time (DST) compared with the current...
Influenza-Linked Hospitalization Rate High in 2024 to 2025 Flu Season
WEDNESDAY, Sept. 17, 2025 -- The cumulative influenza-associated hospitalization rate for the 2024 to 2025 season surpassed all end-of-season rates during the period beginning...
RSV Vaccine Prevents RSV-Linked Hospitalization Among Older Adults Over Two Seasons
FRIDAY, Sept. 12, 2025 -- The respiratory syncytial virus (RSV) vaccine reduces RSV-associated hospitalization among older adults over two seasons, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.